Teladoc Health (NYSE:TDOC) Releases Q1 2025 Earnings Guidance

Teladoc Health (NYSE:TDOC) issued an update on its first quarter 2025 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of -0.400–0.150 for the period, compared to the consensus estimate of -0.370. The company issued revenue guidance of $608.0 million-$629.0 million, compared to the consensus revenue estimate of $633.0 million. Teladoc Health also updated its FY 2025 guidance to -1.100–0.500 EPS.

Teladoc Health Stock Performance

TDOC traded down $1.26 during trading hours on Thursday, hitting $9.73. The company’s stock had a trading volume of 11,469,450 shares, compared to its average volume of 8,110,355. Teladoc Health has a fifty-two week low of $6.76 and a fifty-two week high of $15.95. The company has a current ratio of 1.73, a quick ratio of 1.69 and a debt-to-equity ratio of 0.66. The firm has a market capitalization of $1.68 billion, a PE ratio of -1.69 and a beta of 1.04. The company has a 50-day simple moving average of $10.61 and a 200 day simple moving average of $9.53.

Teladoc Health (NYSE:TDOC) last posted its earnings results on Wednesday, February 26th. The health services provider reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.07). Teladoc Health had a negative net margin of 37.91% and a negative return on equity of 10.06%. The business had revenue of $640.49 million during the quarter, compared to analyst estimates of $639.44 million. As a group, sell-side analysts expect that Teladoc Health will post -1.16 EPS for the current year.

Analyst Upgrades and Downgrades

TDOC has been the subject of a number of research reports. Royal Bank of Canada increased their price target on Teladoc Health from $11.00 to $12.00 and gave the company an “outperform” rating in a research note on Friday, January 24th. Needham & Company LLC reaffirmed a “hold” rating on shares of Teladoc Health in a research note on Thursday. Barclays increased their price target on Teladoc Health from $10.00 to $12.00 and gave the company an “overweight” rating in a research note on Thursday, October 31st. Piper Sandler decreased their price target on Teladoc Health from $13.00 to $12.00 and set an “overweight” rating for the company in a research note on Thursday. Finally, The Goldman Sachs Group raised their price objective on Teladoc Health from $14.00 to $16.00 and gave the stock a “buy” rating in a research note on Tuesday, February 18th. Eleven equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, Teladoc Health presently has a consensus rating of “Hold” and a consensus target price of $11.44.

Insider Buying and Selling

In related news, insider Carlos Nueno sold 2,389 shares of the company’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $11.93, for a total value of $28,500.77. Following the completion of the transaction, the insider now directly owns 2,890 shares of the company’s stock, valued at approximately $34,477.70. This represents a 45.25 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.95% of the company’s stock.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.